Merck, ATG002-1KT, A549 EGFR Antigen Panel Cell Lines

General description
This product is a panel of three (3) genetically modified cell lines involving the EGFR gene. The panel consists of a EGFR knockout cell line (EGFR⁻/⁻) as well as a EGFRlow and a EGFRhigh expression cell line. The EGFR⁻/⁻ cell line was generated using CompoZr® Zinc Finger Nuclease technology, and the two EGFR expression cell lines were generated using MISSION® lentivirus. The EGFRlow and EGFRhigh cell lines express EGFR at low and high levels relative to the EGFR⁻/⁻ cell line (EGFRhigh > EGFRlow > EGFR⁻/⁻) as measured via fluorescence-activated cell sorting (FACS). As a comparison, wild type A549 cells demonstrate EGFRmedium expression as measured via FACS.

The STR profile of these cell lines match that of its parental cell line - ECACC catalog number 86012804.
Biochem/physiol Actions
Derived from a 58 year old Caucasian male. The cells can synthesise lecithin utilising the cytidine diphosphocholine pathway. Occasional cells may also contain inclusion bodies although they are not known to carry any human pathogen.
Features and Benefits
The A549 EGFR antigen panel cell lines feature EGFR expressed at varying levels (KO, low, and high). These cell lines enable researchers to screen and evaluate the efficacy and potency of EGFR-targeted immunotherapies in a biologically-relevant cellular research model.
Analysis Note
Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, and short terminal repeat (STR) analysis for cell line identification.
Other Notes
ATG002A-1VL: A549 EGFR Knockout
ATG002B-1VL: A549 EGFR Low
ATG002C-1VL: A549 EGFR High
Legal Information
MISSION Use Licenses Agreement

ZFN Use Licenses Agreement
CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany